ERAS
Price
$1.38
Change
-$0.07 (-4.83%)
Updated
Jun 25, 04:59 PM (EDT)
Capitalization
390.94M
42 days until earnings call
KALV
Price
$11.68
Change
-$0.02 (-0.17%)
Updated
Jun 25, 04:59 PM (EDT)
Capitalization
580.68M
7 days until earnings call
Interact to see
Advertisement

ERAS vs KALV

Header iconERAS vs KALV Comparison
Open Charts ERAS vs KALVBanner chart's image
Erasca
Price$1.38
Change-$0.07 (-4.83%)
Volume$24.97K
Capitalization390.94M
KalVista Pharmaceuticals
Price$11.68
Change-$0.02 (-0.17%)
Volume$8.96K
Capitalization580.68M
ERAS vs KALV Comparison Chart in %
Loading...
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KALV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ERAS vs. KALV commentary
Jun 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ERAS is a Buy and KALV is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 26, 2025
Stock price -- (ERAS: $1.38 vs. KALV: $11.68)
Brand notoriety: ERAS and KALV are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ERAS: 62% vs. KALV: 179%
Market capitalization -- ERAS: $390.94M vs. KALV: $580.68M
ERAS [@Biotechnology] is valued at $390.94M. KALV’s [@Biotechnology] market capitalization is $580.68M. The market cap for tickers in the [@Biotechnology] industry ranges from $312.97B to $0. The average market capitalization across the [@Biotechnology] industry is $2.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ERAS’s FA Score shows that 0 FA rating(s) are green whileKALV’s FA Score has 0 green FA rating(s).

  • ERAS’s FA Score: 0 green, 5 red.
  • KALV’s FA Score: 0 green, 5 red.
According to our system of comparison, KALV is a better buy in the long-term than ERAS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ERAS’s TA Score shows that 5 TA indicator(s) are bullish while KALV’s TA Score has 3 bullish TA indicator(s).

  • ERAS’s TA Score: 5 bullish, 5 bearish.
  • KALV’s TA Score: 3 bullish, 7 bearish.
According to our system of comparison, ERAS is a better buy in the short-term than KALV.

Price Growth

ERAS (@Biotechnology) experienced а -1.43% price change this week, while KALV (@Biotechnology) price change was -5.12% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.95%. For the same industry, the average monthly price growth was +31.79%, and the average quarterly price growth was +15.79%.

Reported Earning Dates

ERAS is expected to report earnings on Aug 07, 2025.

KALV is expected to report earnings on Sep 04, 2025.

Industries' Descriptions

@Biotechnology (+1.95% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KALV($581M) has a higher market cap than ERAS($391M). KALV YTD gains are higher at: 37.898 vs. ERAS (-45.020). ERAS has higher annual earnings (EBITDA): -150.24M vs. KALV (-173.23M). ERAS has more cash in the bank: 305M vs. KALV (253M). KALV has less debt than ERAS: KALV (5.78M) vs ERAS (50.8M). ERAS (0) and KALV (0) have equivalent revenues.
ERASKALVERAS / KALV
Capitalization391M581M67%
EBITDA-150.24M-173.23M87%
Gain YTD-45.02037.898-119%
P/E RatioN/AN/A-
Revenue00-
Total Cash305M253M121%
Total Debt50.8M5.78M879%
FUNDAMENTALS RATINGS
KALV: Fundamental Ratings
KALV
OUTLOOK RATING
1..100
55
VALUATION
overvalued / fair valued / undervalued
1..100
50
Fair valued
PROFIT vs RISK RATING
1..100
96
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
47
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ERASKALV
RSI
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
83%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
81%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
86%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
87%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
87%
Advances
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 17 days ago
79%
Declines
ODDS (%)
Bearish Trend 9 days ago
88%
Bearish Trend 2 days ago
87%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
89%
Aroon
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KALV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LCEAX18.68N/A
N/A
Invesco Diversified Dividend A
MXMTX10.34N/A
N/A
Empower Small Cap Growth Investor
TQSAX22.94N/A
N/A
T. Rowe Price Integrated US SMCC Eq Adv
JECTX17.32N/A
N/A
Janus Henderson Global Sust Eq C
APDRX33.73-0.10
-0.30%
Artisan Global Opportunities Advisor